The cellular and molecular basis of the Lyt‐1+2− T cell‐mediated tumor‐eradicating mechanism in vivo
- 1 January 1986
- Vol. 4 (1), 19-23
- https://doi.org/10.1002/bies.950040106
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- The augmentation of tumor-specific immunity by virus helpCancer Immunology, Immunotherapy, 1986
- Mechanisms of Rejection and Prolongation of Vascularized Organ AllograftsImmunological Reviews, 1984
- The augmentation of tumor‐specific immunity by virus help. II. Enhanced induction of cytotoxic T lymphocyte and antibody responses to tumor antigens by vaccinia virus‐reactive helper T cellsEuropean Journal of Immunology, 1983
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982
- Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes.The Journal of Experimental Medicine, 1981
- Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection.The Journal of Experimental Medicine, 1981
- Thy and Ly markers on lymphocytes initiating tumor rejectionCellular Immunology, 1981
- Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes.The Journal of Experimental Medicine, 1980
- Regulatory functions of hapten-reactive helper and suppressor T lymphocytes. III. Amplification of a generation of tumor-specific killer T-lymphocyte activities by suppressor T-cell-depleted hapten-reactive T lymphocytes.The Journal of Experimental Medicine, 1979
- Cell-Mediated Cytotoxicity, Allograft Rejection, and Tumor ImmunityAdvances in Immunology, 1974